About NovellusDx
NovellusDx is a Healthcare company based in Jerusalem (Israel) founded in 2011. Developer of technology for precision cancer diagnosis and therapies. NovellusDx has raised $85.5 million across 4 funding rounds from investors including Novartis, Orbimed and GSK. Its focus areas include Life Sciences, Genomics, Genomics Services and Sequencing.
Company details
NovellusDx was founded in 2011 in Jerusalem, Israel, within the biotechnology sector focused on precision medicine. Technology is developed to track outcomes of DNA mutations, assess their functional and clinical impacts, and evaluate drug effects on specific tumors. Operations center on advancing diagnostic and therapeutic tools for oncology, with applications in personalized cancer treatment strategies.
- Headquarters Jerusalem, Israel
- SectorsHealthcare
- Email••••••••
- Website novellusdx.com
- Social LinkedIn
- Total Equity Funding$85.5M (USD)
in 4 rounds
- Latest Funding Round$57M (USD), Series C
Sep 2020
- InvestorsNovartis
& 9 more
Funding Insights of NovellusDx
NovellusDx has successfully raised a total of $85.5M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $57 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $85.5M
- Total Rounds 4
- Last Round Series C — $57M
- First Round $10M
(Dec 2015)
- Investors Count 10
All 4 funding rounds of NovellusDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $57M | Series C | – | Pontifax, Orbimed | |
| Apr 2018 | $6M | Series B | – | 3B FUTURE Health Fund, Windham Venture Partners | – |
| Jun 2016 | $12.5M | Series B | – | – | |
| Dec 2015 | $10M | Series A | – | – |
10 investors in total: 10 institutional.
Investors in NovellusDx
NovellusDx has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Orbimed and GSK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pontifax Venture Capital is focused on life sciences investments. | pontifax.com | Herzeliya, Israel | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Early-stage healthcare investments are made by this fund. | helsinninvestmentfund.com | Luxembourg, Luxembourg | ||
Investment in biotech technologies is managed for societal impact. | bcif.com.au | Melbourne, Australia | ||
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland | |
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States | ||
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom | |
Windham Capital Partners is focused on HealthTech venture investments. | windhamvp.com | New York, United States |
Investor details for NovellusDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of NovellusDx
3 dated milestones of NovellusDx across 9 years, from founding to its latest funding, stage changes and deals.
- Founded NovellusDx is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series C, of $57.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novellusdx
Complete news archive for NovellusDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NovellusDx
NovellusDx was founded in 2011 and raised its 1st funding round 4 years after it was founded.
NovellusDx is headquartered in Jerusalem, Israel. It is registered at Jerusalem, Jerusalem District, Israel.
NovellusDx is a funded company, having raised a total of $85.5M across 4 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Dec 2015.
NovellusDx was founded in 2011 in Jerusalem, Israel, within the biotechnology sector focused on precision medicine. Technology is developed to track outcomes of DNA mutations, assess their functional and clinical impacts, and evaluate drug effects on specific tumors. Operations center on advancing diagnostic and therapeutic tools for oncology, with applications in personalized cancer treatment strategies.
NovellusDx has 10 investors. Key investors include Novartis, Orbimed, GSK, HBM Healthcare Investments, and Pontifax Venture Capital.